$Selecting treatment options in refractory metastatic colorectal cancer$

Selecting treatment options in refractory metastatic colorectal cancer

Margaret Byrne, Muhammad Wasif Saif Northwell Health Cancer Institute, Donald and Barbara Zucker School of Medicine at Hofstra, Lake Success, NY, USA Abstract: Survival of patients with metastatic colorectal cancer (mCRC) has significantly improved in the last decade. Survival gains are not driven...

Full description

Bibliographic Details
Main Authors:	Byrne M, Saif MW
Format:	Article
Language:	English
Published:	Dove Medical Press 2019-03-01
Series:	OncoTargets and Therapy
Subjects:	TKI fluoropyrimidine bevacizumab cetuximab panitumumab PD-1 inhibitor FOLFIRI epidermal growth factor receptor vascular endothelial growth factor receptor platelet-derived growth factor receptors KRAS NRAS HER2 advanced colon cancer refractory lonsurf regorafenib
Online Access:	https://www.dovepress.com/selecting-treatment-options-in-refractory-metastatic-colorectal-cancer-peer-reviewed-article-OTT

Similar Items

A Case of Panitumumab-Responsive Metastatic Rectal Cancer Initially Refractory to Cetuximab
by: Yuta Kasagi, et al.
Published: (2013-07-01)

Targeting EGFR in Esophagogastric Cancer
by: Steven B. Maron, et al.
Published: (2020-12-01)

Mécanismes de résistance au cetuximab et influence des associations de traitement dans des lignées cellulaires de cancers de voies aérodigestives supérieures
by: Rebucci, Magali
Published: (2010)

<it>EGFR</it> gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysis
by: Yang Zu-Yao, et al.
Published: (2012-08-01)

Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer
by: Hans Urban, et al.
Published: (2020-10-01)

Cicatricial ectropion and madarosis associated with panitumumab treatment of metastatic colorectal cancer
by: Haoxing D. Jin, et al.
Published: (2020-09-01)

Cetuximab in treatment of metastatic colorectal cancer: background and clinical observation
by: A. D. Darenskaya, et al.
Published: (2018-11-01)

Recent advances of novel targeted therapy for squamous cell carcinoma of the head and neck
by: Jed A. Katzel, et al.
Published: (2011-12-01)

Efficacy and Immune Mechanisms of Cetuximab for the Treatment of Metastatic Colorectal Cancer
by: Hao Zhuang, et al.
Published: (2011-12-01)

Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials
by: Ze-Hao Huang, et al.
Published: (2018-11-01)

METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
by: N. A. Avxentyev, et al.
Published: (2016-09-01)

The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka
by: Nirmala Dushyanthi Sirisena, et al.
Published: (2017-08-01)

First-line molecular therapies in the treatment of metastatic colorectal cancer – a literature-based review of phases II and III trials
by: Vogel Arndt, et al.
Published: (2018-05-01)

Strategies for monitoring and combating resistance to combination kinase inhibitors for cancer therapy
by: Leanne G. Ahronian, et al.
Published: (2017-04-01)

Efficacy of Cetuximab in Combination with FOLFIRI in a Patient with KRAS Wild-Type Metastatic Anal Cancer
by: Hanna Barmettler, et al.
Published: (2012-08-01)

Effects of Monoclonal Antibody Cetuximab on Proliferation of Non-small Cell Lung Cancer Cell lines
by: Zhen CHEN, et al.
Published: (2010-08-01)

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
by: Caglayan Geredeli, et al.
Published: (2018-03-01)

Sequential therapy with bevacizumab and EGFR inhibitors for metastatic colorectal carcinoma: a national registry-based analysis
by: Buchler T, et al.
Published: (2018-12-01)

The Combination of Afatinib and Bevacizumab in Untreated EGFR-Mutated Advanced Lung Adenocarcinoma: A Multicenter Observational Study
by: Ping-Chih Hsu, et al.
Published: (2020-10-01)

First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis
by: Alessandro Ottaiano, et al.
Published: (2018-05-01)

The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
by: Alexios Matikas, et al.
Published: (2015-03-01)

The Addition of EGFR Inhibitors in Neoadjuvant Therapy for KRAS-Wild Type Locally Advanced Rectal Cancer Patients: A Systematic Review and Meta-Analysis
by: Xi Zhong, et al.
Published: (2020-05-01)

Detection and Analysis of EGFR and KRAS Mutations  in the Patients with Lung Squamous Cell Carcinomas
by: Hui ZHANG, et al.
Published: (2015-10-01)

Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma
by: Hui ZHANG, et al.
Published: (2015-11-01)

Analysis of research on the benefits of clinical and economic effectiveness, safety of innovative drug cetuximab in the treatment of colorectal cancer
by: Elena Litvinova
Published: (2019-04-01)

Epidermal growth factor receptor inhibitor in advanced basal cell carcinoma
by: Amir Amirabadi, et al.
Published: (2021-05-01)

Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
by: Lavacchi D, et al.
Published: (2019-09-01)

Modern possibilities of targeted therapy in metastatic colorectal cancer
by: V A Gorbunova
Published: (2015-12-01)

Efficacy of bevacizumab versus epidermal growth factor receptor inhibitors for wild-type RAS metastatic colorectal cancer: a meta-analysis
by: Jiang W, et al.
Published: (2018-07-01)

Retrospective analysis to assess the feasibility of escalated dose of nimotuzumab in patients with locally advanced head and neck cancer
by: Nagraj Gururaj Huilgol, et al.
Published: (2017-01-01)

Advances in Variations of Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor-2 Status in Metastatic Breast Cancer
by: Yuan Yuan, et al.
Published: (2013-06-01)

Epidermal growth factor receptor pathway as therapeutic development in head and neck cancers: present and future
by: Chancellor E. Donald, et al.
Published: (2011-12-01)

PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment
by: Chang CY, et al.
Published: (2021-03-01)

Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer
by: Yu-Chang Liu, et al.
Published: (2020-08-01)

Potential Role of EGF and EGFR in Tongue Coating Formation
by: Yi-Shuang Tang, et al.
Published: (2016-12-01)

Role of Receptor Tyrosine Kinase Signaling in Renal Fibrosis
by: Feng Liu, et al.
Published: (2016-06-01)

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
by: Sho Watanabe, et al.
Published: (2021-03-01)

Synthetic epidermal growth factor receptor (EGFR)-mitochondria desired axles-based split green-fluorescent-protein (GFP) could screen for the signaling molecules that overcome the drug resistance to tyrosine kinase inhibitor (TKI)
by: Robert Chen, et al.
Published: (2016-06-01)

Immuno- and biochemistry of sugars of the EGF receptor in cancer
by: Dolman, Carl David
Published: (1992)

Gallbladder Adenocarcinoma, Potential Target for Anti-Her-2 Therapy
by: Ghazi Zafar, et al.
Published: (2020-08-01)